We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.10 | 9.70 | 10.50 | 10.10 | 10.10 | 10.10 | 156,890 | 08:00:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.83 | 93.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/9/2023 09:17 | Normal behaviour / reaction ??? - It is 'normal' for DECENT people to give folks 'the benefit of the doubt' when first encountering others... (No reason not to trust a fellow life traveller...despite warnings from a few, as to the 'honesty' of the 'new aquaintances' , specially if the 'new aquaintances' appear to hold/express similar aims.views) However,when those 'new aquaintances' repeatedly provide indications as to their REAL intentions - LIES,FALSE CLAIMS... ( STEALING ??? )... puts their 'honesty' in question. There comes a time when DECENT people react by withdrawing their 'faith' in those 'new aquaintances' .... Some, perhaps for selfish reasons, WILL CONtinue to promote/defend those 'new aquaintances' ... even when 'DIShonesty' is obvios to DECENT people,who tend not to over react but simply deduce = 'Enough is enough'. . This appears to be the case here with these forums. . The numbers of DECENT posters on these forums over the YEARS who have decided = 'Enough is enough',and simply withdrawn - leaving the manipulators to their practices - IS in it's self evident that DECENT people ' Don't want anything to do with DIShonesty'. | the real lozan | |
11/9/2023 20:21 | Moderna is doubling down in cancer vaccines and cell therapies with a new Immatics research partnership that could eventually top $1.7 billion in milestones. The deal, which features a $120 million upfront payment | marcusl2 | |
11/9/2023 20:16 | SC129 (partnered up to $624m, plus single digit royalties on sales.Rights to SC129 for cell therapy products retained by Scancell) Pancreatic cancer It is one of five monoclonal antibodies (mAbs) currently in Scancell's portfolio, said the company, with the methodology able to identify "many more mAbs against glycan targets in the future". We now know that Scancell is working on other undisclosed ones in earlier stages of preclinical development. | marcusl2 | |
11/9/2023 12:31 | if you want to go back through my history on no risk it always refers back to scib1 """ SCIB1 is now in a clinical trial (SCOPE) in combination with checkpoint inhibitors and is showing clinical responses in the majority of patients.""" if that quote from the upcoming presentation is correct hate to say it ......... I was right ! £70m .... lol | inanaco | |
11/9/2023 12:23 | """ SCIB1 is now in a clinical trial (SCOPE) in combination with checkpoint inhibitors and is showing clinical responses in the majority of patients.""" you could follow the clever folks ... Bermuda, Crumbs and C7 out of the share at a MCAP of £70m ............. clearly the risk reward is not here apparently Trinty values it a bit higher | inanaco | |
11/9/2023 12:02 | still scancell already has an adjuvant trial under its belt ........... proven to work | inanaco | |
11/9/2023 11:59 | ouch ! In fact, Rubin added, data coming from an ongoing, single-arm phase 1 solid tumor trial "doesn't look as promising as what we've seen in the adjuvant melanoma space." That trial remains ongoing, but recruitment ended in February, according to the clinical trial record. | inanaco | |
11/9/2023 11:58 | all exciting More than three-quarters of patients (78.6%) with high-risk melanoma treated with mRNA-4157 in addition to Keytruda had recurrence-free survival at 18 months compared to 62.2% of patients in the comparator arm, which received Keytruda alone, according to new data presented at the 2023 American Association for Cancer Research (AACR) annual meeting. That equates to a 44% reduction in recurrence or death. There were no grade 4 or 5 side effects due to the mRNA-4157 reported in treated patients. The 157-patient trial was randomized 2:1. Merck and Moderna have plans to launch into a phase 3 trial before the end of the year. Rubin wouldn’t comment on previous teases from Moderna’s top brass that the companies were working with regulators on using the accelerated approval pathway, noting only that mRNA-4157's FDA breakthrough designation gives it a leg up. | inanaco | |
11/9/2023 11:55 | P7 which one has failed optiva keytruda and yervoy or scib1 when you look at modernas personal vaccine success in the adjuvant setting ... why not look at the same vaccine against solid cancer, same indication melanoma Scancells target | inanaco | |
10/9/2023 22:11 | Poster next week will show the light. | golcheja | |
10/9/2023 19:02 | Inane, looks like you will be the last man standing, Bermuda, Crumbs and Chelsea have all bailed. It's not just Private Investors, Chipman, Holloway, Badfellow and Evans have all seen the writing on the wall. | panama7 | |
09/9/2023 20:59 | SC129 (partnered up to $624m, plus single digit royalties on sales.Rights to SC129 for cell therapy products retained by Scancell) Pancreatic cancer SC134 (probably doing a phase 1/2 trial ourselves) • TCB lead target • Small cell lung cancer SC2811 • Stimulatory mAb target • • Any solid tumour SC88 • Lewisacx • Colorectal cancer SC27 • Lewisy • Ovarian cancer PLUS other undisclosed ones in earlier stages of preclinical development Avidimab | marcusl2 | |
09/9/2023 13:02 | Don`t forget about SC2811 iSC2811 – costimulates TILs resulting in anti-tumour immunity and enhances T cell engraftment for CAR-T development Ultraspecific SSEA4 mAb – lead AvidiMab® modified clinical candidate SC2811 mediates tumour-free survival in preclinical models iSC2811 enhances T cell engraftment and prevents exhaustion Potential for improving CAR-T approaches | marcusl2 | |
09/9/2023 10:56 | Colin From accounts commented ..... But Loz i just bought .. I succumbed to buying cheap ...... as a potential way to make a profit ... I have learned by my losses .... I am smart The Tuned Combine .... missing from todays Kept mans diary . Gerald Commented ... lovely be that more more | inanaco | |
09/9/2023 09:36 | A castle built on sand = A fool's paradise ... It should come as no surprise that following YEARS of trHYPE FALSE CLAIMS and LIES, that WE ALL - that is DECENT folks, see SCLP forums and SCLP S P... falling apart. The creation of 'A toxic,distasteful enviornment' by 'ONE man and HIS gang'. The number of reasonable folks who have left these forums and the number of folks who have sold/ reduced. become disinterested / been turned off from investing in SCLP,,,is astonishing. A floundering S P , lack of volumes tells those with eyes to see - the REALITY The latest departures from M F F F and their subsequent nasty treatment shows why they CHOSE to 'call it a day' and 'tells those with eyes to see - the REALITY' . The creation of 'A toxic,distasteful enviornment' by 'ONE man and HIS gang'in the way the Boris (EGOboy's former HERO liar) has effected the UK -'tells those with eyes to see - the REALITY' The creation of 'A toxic,distasteful enviornment' by 'ONE man and HIS gang' leaves SCLP *A desert occupied by snakes and spiders* Best avoided by DECENT FOLKS . A castle built on sand, based on FALSE CLAIMS and LIES = A fool's paradise ... Destined to FALL ...investments to FAIL . | the real lozan | |
08/9/2023 17:55 | Colin From Accounts commented what a wonderful life .... bit sticky in my salesman's Mondeo with plush PVC | inanaco | |
08/9/2023 17:51 | sounds like Clarkson has arrived ... "tuned up combine" another year of successful planning for .... Log Day Diary of the Kept Man | inanaco | |
08/9/2023 17:21 | Quite a busy week - Mon - Clear space in barn to house 'winter fuel log' delivery Tue - Nadia called by ...stayed the night Wed - M. Bruno phoned to check and deliver 1st truckfull of logs Thu - !st logs in,stacked,dry and under cover Fri - Combine tuned up to harvest sunflowers in the fields around us Still at it as I post ...Now 36 C in the sun . Yet another week where inane'n'co embarrasses HIMself AGAIN...and M F F F display what they have always been. | the real lozan | |
08/9/2023 15:36 | Once again the All In one share No risk mantra has been shown to be a pretty stupid call if you invested here. Witless,Pot less and now Car Park less all down to one Crumbs post-he must hate that he has no such influence and compared to Bermuda he is out of his depth science wise and with Ruck out of his depth making money wise. Meanwhile Crumbs has done with one post what normally takes Nana about 500 to make the share price to move in the wrong direction. | ivyspivey | |
08/9/2023 13:16 | The Kept Man ......... its not a prediction | inanaco | |
08/9/2023 12:58 | a reminder of Bermudas post I am not trading Scancell. I have clearly explained my reasons for reducing my holdings and whilst it may suit you and a small group of others to believe/portray this as an attempt to buy back for a quick 20%, it is absolutely not the case. You should know that in my entire posting history, I have only ever posted as I see it and never to suit a trade - that's simply not how I invest in bios. I have also never advised anyone to buy or sell whilst doing the opposite myself. Rather than trying to discredit other long term holders to blindly defend Scancell, you might do better to accept that they simply have a different view and investment strategy. I still believe that Scancell has great potential and will watch from a distance. I will continue to post any info./research/links that may be helpful or relevant but other than that I will leave a much reduced holding in the bottom drawer and wait and see. If there is any news or a corporate event that shifts the risk/reward ratio back then I will happily pay more to buy back the stock I have sold but right now things are tough out there and there is a way to go. | inanaco |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions